SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001213900-25-011202 from Apimeds Pharmaceuticals US, Inc. (APUS)

Apimeds Pharmaceuticals US, Inc.
Date: Feb. 7, 2025 · CIK: 0001894525 · Accession: 0001213900-25-011202

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-282324

Date
February 11, 2025
Author
D. Boral Capital LLC
Form
CORRESP
Company
Apimeds Pharmaceuticals US, Inc.

Letter

D. Boral Capital LLC

590 Madison Ave., 39th Floor

New York, NY 10022

February 7, 2025

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

100 F St., NE

Washington, D.C. 20549

Re: Apimeds Pharmaceuticals US, Inc.

Registration Statement on Form S-1 (File No. 333-282324)

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, D. Boral Capital LLC, as representative of the underwriters, hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 5:00 p.m. Eastern Time on Tuesday, February 11, 2025, or as soon thereafter as practicable.

Pursuant to Rule 460 under the Securities Act, please be advised that there will be distributed to each underwriter, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.

Very truly yours,
D. Boral Capital LLC

Show Raw Text
CORRESP
1
filename1.htm

D. Boral Capital LLC

590 Madison Ave., 39th Floor

New York, NY 10022

February
7, 2025

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

100 F St., NE

Washington, D.C. 20549

    Re:
    Apimeds Pharmaceuticals US, Inc.

    Registration Statement on Form S-1 (File No. 333-282324)

Ladies and Gentlemen:

Pursuant to Rule 461
of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, D. Boral
Capital LLC, as representative of the underwriters, hereby requests acceleration of the effective date of the above-referenced Registration
Statement so that it will become effective at 5:00 p.m. Eastern Time on Tuesday, February 11, 2025, or as soon thereafter as practicable.

Pursuant to Rule 460 under
the Securities Act, please be advised that there will be distributed to each underwriter, who is reasonably anticipated to be invited
to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable
to secure adequate distribution of the preliminary prospectus.

The undersigned confirms that
it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they
have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with
the above-referenced issue.

    Very truly yours,

    D. Boral Capital LLC

    By:
    /s/ Philip Wiederlight

    Name:
    Philip Wiederlight

    Title:
    COO and Supervisory Principal